hydroxychloroquine
Ligand Summary
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). In March 2020, FDA issued an emergency use authorization (EUA) for hydroxychloroquine and chloroquine in the treatment of COVID-10. EUA was revoked in June 2020. Data from various published randomized, controlled clinical trials and retrospective, cohort studies have not substantiated initial reports of efficacy of 4-aminoquinoline antimalarials for treatment of COVID-19.
UNII: 4QWG6N8QKH
PubChem: 3652
Guide to Pharmacology: 7198
ChEMBL: CHEMBL1535
DrugCentral: 1395
LyCHI: DTMVCQWRY5XU
Target Activities
11 Activities
Items per page:
10
1 – 10 of 11
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
Ki | ||||||
Ki | ||||||
Ki | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ANTAGONIST | |||||
IC50 | ANTAGONIST | |||||